Schuh A, Priglinger S, Messmer E M
Augenklinik, Klinikum der Universität München, Campus Innenstadt, Mathildenstr. 8, 80336, München, Deutschland.
Ophthalmologe. 2019 Oct;116(10):982-988. doi: 10.1007/s00347-019-00955-z.
Meibomian gland dysfunction (MGD) is a common cause of dry eye disease. Intense pulsed light (IPL) treatment is a new and approved therapeutic option for MGD. The treatment consists of 2-4 sessions where light impulses are applied to the lower lid and temporal lid margin. The IPL technique is a safe form of treatment when the required safety precautions are followed. Current studies document an improvement of patients' subjective symptoms and objectively measured clinical parameters.
睑板腺功能障碍(MGD)是干眼疾病的常见病因。强脉冲光(IPL)治疗是一种针对MGD的新型且已获批准的治疗选择。该治疗包括2至4次疗程,在此过程中,光脉冲会作用于下眼睑和颞侧睑缘。当遵循所需的安全预防措施时,IPL技术是一种安全的治疗方式。目前的研究记录了患者主观症状的改善以及客观测量的临床参数的改善。